In vitro pharmacodynamic properties of colistin and colistin methanesulfonate against Pseudomonas aeruginosa isolates from patients with cystic fibrosis

被引:197
|
作者
Li, J
Turnidge, J
Milne, R
Nation, RL
Coulthard, K
机构
[1] Univ S Australia, Pharmaceut Res Ctr, Adelaide, SA 5001, Australia
[2] Womens & Childrens Hosp, Dept Infect Dis, Adelaide, SA, Australia
[3] Womens & Childrens Hosp, Dept Pharm, Adelaide, SA, Australia
关键词
D O I
10.1128/AAC.45.3.781-785.2001
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
The in vitro pharmacodynamic properties of colistin and colistin methanesulfonate were investigated by studying the MICs, time-kill kinetics, and postantibiotic effect (PAE) against mucoid and nonmucoid strains of Pseudomonas aeruginosa isolated from patients with cystic fibrosis, Twenty-three clinical strains, including multiresistant strains, and one type strain were selected for MIC determination. Eleven strains were resistant; MICs for these strains were > 128 mg/liter, For the susceptible strains, MICs of colistin ranged from 1 to 4 mg/liter, while the MICs of colistin methanesulfonate were significantly higher and ranged from 4 to 16 mg/liter, The time-kill kinetics were investigated with three strains at drug concentrations ranging from 0.5 to 64 times the MIC. Colistin showed extremely rapid killing, resulting in complete elimination at the highest concentrations within 5 min, while colistin methanesulfonate killed more slowly, requiring a concentration of 16 times the MIC to achieve complete killing within 24 h, Colistin exhibited a significant PAE of 2 to 3 h at 16 times the MIC against the three strains after 15 min of exposure. For colistin methanesulfonate, PAEs were shorter at the concentrations tested. Colistin methanesulfonate had lower overall bactericidal and postantibiotic activities than colistin, even when adjusted for differences in MICs, Our data suggest that doses of colistin methanesulfonate higher than the recommended 2 to 3 mg/kg of body weight every 12 h may be required for the effective treatment of P. aeruginosa infections in cystic fibrosis patients.
引用
收藏
页码:781 / 785
页数:5
相关论文
共 50 条
  • [31] Eradication of Pseudomonas aeruginosa with inhaled colistin in adults with non-cystic fibrosis bronchiectasis
    Blanco-Aparicio, Marina
    Luis Saleta Canosa, Jesus
    Valino Lopez, Paz
    Martin Egana, Maria Teresa
    Vidal Garcia, Iria
    Montero Martinez, Carmen
    CHRONIC RESPIRATORY DISEASE, 2019, 16
  • [32] In vitro Activities of the Novel Ceragenin CSA-13, Alone or in Combination with Colistin, Tobramycin, and Ciprofloxacin, against Pseudomonas aeruginosa Strains Isolated from Cystic Fibrosis Patients
    Bozkurt-Guzel, Cagla
    Savage, Paul B.
    Gerceker, Ayse Alev
    CHEMOTHERAPY, 2011, 57 (06) : 505 - 510
  • [33] In vitro activity of doripenem against Pseudomonas aeruginosa and Burkholderia cepacia isolates from both cystic fibrosis and non-cystic fibrosis patients
    Traczewski, MM
    Brown, SD
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2006, 50 (02) : 819 - 821
  • [34] PmrB Mutations Promote Polymyxin Resistance of Pseudomonas aeruginosa Isolated from Colistin-Treated Cystic Fibrosis Patients
    Moskowitz, Samuel M.
    Brannon, Mark K.
    Dasgupta, Nandini
    Pier, Miyuki
    Sgambati, Nicole
    Miller, Amanda K.
    Selgrade, Sara E.
    Miller, Samuel I.
    Denton, Miles
    Conway, Steven P.
    Johansen, Helle K.
    Hoiby, Niels
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2012, 56 (02) : 1019 - 1030
  • [35] The pharmacokinetics of colistin in patients with cystic fibrosis
    Reed, MD
    Stern, RC
    O'Riordan, MA
    Blumer, JL
    JOURNAL OF CLINICAL PHARMACOLOGY, 2001, 41 (06): : 645 - 654
  • [36] IN VITRO ACTIVITY OF CEFTAZIDIME-AVIBACTAM AND COLISTIN AGAINST CARBAPENEM-RESISTANT PSEUDOMONAS AERUGINOSA CLINICAL ISOLATES
    Hosbul, Tugrul
    Aydogan, Canset Nur
    Kaya, Sinem
    Bedir, Rhan
    Ozcan, Hande
    Gumral, Ramazan
    JOURNAL OF ISTANBUL FACULTY OF MEDICINE-ISTANBUL TIP FAKULTESI DERGISI, 2022, 85 (03): : 355 - 361
  • [37] In vitro activity of colistin in combination with N-acetylcysteine against Pseudomonas aeruginosa
    Pallecchi, Lucia
    Pollini, Simona
    Di Maggio, Tiziana
    Girelli, Daniela
    Teri, Antonio
    Cariani, Lisa
    Aliberti, Stefano
    Blasi, Francesco
    Sergio, Francesco
    Rossolini, Gian Maria
    EUROPEAN RESPIRATORY JOURNAL, 2018, 52
  • [38] Eugenol works synergistically with colistin against colistin-resistant Pseudomonas aeruginosa and Klebsiella pneumoniae isolates by enhancing membrane permeability
    Kong, Jingchun
    Wang, Yue
    Yao, Zhuocheng
    Lin, Yishuai
    Zhang, Yi
    Han, Yijia
    Zhou, Tieli
    Ye, Jianzhong
    Cao, Jianming
    MICROBIOLOGY SPECTRUM, 2023, 11 (05):
  • [39] Eugenol works synergistically with colistin against colistin-resistant Pseudomonas aeruginosa and Klebsiella pneumoniae isolates by enhancing membrane permeability
    Kong, Jingchun
    Wang, Yue
    Yao, Zhuocheng
    Lin, Yishuai
    Zhang, Yi
    Han, Yijia
    Zhou, Tieli
    Ye, Jianzhong
    Cao, Jianming
    MICROBIOLOGY SPECTRUM, 2023,
  • [40] In vitro activities of colistin combinations against Pseudomonas aeruginosa isolated from the intensive care unit
    Lopez-Fabal, F.
    Culebras, E.
    Bonilla, I.
    Gomez, M.
    Picazo, J. J.
    REVISTA ESPANOLA DE QUIMIOTERAPIA, 2008, 21 (03) : 189 - 193